Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity. / Jall, Sigrid; De Angelis, Meri; Lundsgaard, Annemarie; Fritzen, Andreas Mæchel; Nicolaisen, Trine Sand; Klein, Anders Bue; Novikoff, Aaron; Sachs, Stephan; Richter, Erik A.; Kiens, Bente; Schramm, Karl-Werner; Tschöp, Matthias H; Stemmer, Kerstin; Clemmensen, Christoffer; Müller, Timo D; Kleinert, Maximilian.

I: Diabetologia, Bind 63, Nr. 6, 2020, s. 1236-1247.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jall, S, De Angelis, M, Lundsgaard, A, Fritzen, AM, Nicolaisen, TS, Klein, AB, Novikoff, A, Sachs, S, Richter, EA, Kiens, B, Schramm, K-W, Tschöp, MH, Stemmer, K, Clemmensen, C, Müller, TD & Kleinert, M 2020, 'Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity', Diabetologia, bind 63, nr. 6, s. 1236-1247. https://doi.org/10.1007/s00125-020-05117-4

APA

Jall, S., De Angelis, M., Lundsgaard, A., Fritzen, A. M., Nicolaisen, T. S., Klein, A. B., ... Kleinert, M. (2020). Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity. Diabetologia, 63(6), 1236-1247. https://doi.org/10.1007/s00125-020-05117-4

Vancouver

Jall S, De Angelis M, Lundsgaard A, Fritzen AM, Nicolaisen TS, Klein AB o.a. Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity. Diabetologia. 2020;63(6):1236-1247. https://doi.org/10.1007/s00125-020-05117-4

Author

Jall, Sigrid ; De Angelis, Meri ; Lundsgaard, Annemarie ; Fritzen, Andreas Mæchel ; Nicolaisen, Trine Sand ; Klein, Anders Bue ; Novikoff, Aaron ; Sachs, Stephan ; Richter, Erik A. ; Kiens, Bente ; Schramm, Karl-Werner ; Tschöp, Matthias H ; Stemmer, Kerstin ; Clemmensen, Christoffer ; Müller, Timo D ; Kleinert, Maximilian. / Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity. I: Diabetologia. 2020 ; Bind 63, Nr. 6. s. 1236-1247.

Bibtex

@article{0fd5ee644a044a168ee8b281d72f356a,
title = "Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity",
abstract = "Aims/Hypothesis: Treatment with the α3β4 nicotinic acetylcholine receptor (nAChR) agonist, 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), improves glucose tolerance in diet-induced obese (DIO) mice, but the physiological and molecular mechanisms are unknown.Methods: DMPP (10 mg/kg body weight, s.c.) was administered either in a single injection (acute) or daily for up to 14 days (chronic) in DIO wild-type (WT) and Chrnb4 knockout (KO) mice and glucose tolerance, tissue-specific tracer-based glucose metabolism, and insulin signalling were assessed.Results: In WT mice, but not in Chrnb4 KO mice, single acute treatment with DMPP induced transient hyperglycaemia, which was accompanied by high plasma adrenaline (epinephrine) levels, upregulated hepatic gluconeogenic genes, and decreased hepatic glycogen content. In contrast to these acute effects, chronic DMPP treatment in WT mice elicited improvements in glucose tolerance already evident after three consecutive days of DMPP treatment. After seven days of DMPP treatment, glucose tolerance was markedly improved, also in comparison with mice that were pair-fed to DMPP-treated mice. The glycaemic benefit of chronic DMPP was absent in Chrnb4 KO mice. Chronic DMPP increased insulin-stimulated glucose clearance into brown adipose tissue (+69{\%}), heart (+93{\%}), gastrocnemius muscle (+74{\%}) and quadriceps muscle (+59{\%}), with no effect in white adipose tissues. After chronic DMPP treatment, plasma adrenaline levels did not increase following an injection with DMPP. In glucose-stimulated skeletal muscle, we detected a decreased phosphorylation of the inhibitory Ser640 phosphorylation site on glycogen synthase and a congruent increase in glycogen accumulation following chronic DMPP treatment.Conclusions/Interpretation: Our data suggest that DMPP acutely induces adrenaline release and hepatic glycogenolysis, while chronic DMPP-mediated activation of β4-containing nAChRs improves peripheral insulin sensitivity independently of changes in body weight via mechanisms that could involve increased non-oxidative glucose disposal into skeletal muscle.",
keywords = "Faculty of Science, Catecholamine, Glucose metabolism, Glucose tolerance, Hyperglycaemia, Insulin sensitivity, Nicotinic acetylcholine receptor, Pharmacology",
author = "Sigrid Jall and {De Angelis}, Meri and Annemarie Lundsgaard and Fritzen, {Andreas M{\ae}chel} and Nicolaisen, {Trine Sand} and Klein, {Anders Bue} and Aaron Novikoff and Stephan Sachs and Richter, {Erik A.} and Bente Kiens and Karl-Werner Schramm and Tsch{\"o}p, {Matthias H} and Kerstin Stemmer and Christoffer Clemmensen and M{\"u}ller, {Timo D} and Maximilian Kleinert",
note = "CURIS 2020 NEXS 040",
year = "2020",
doi = "10.1007/s00125-020-05117-4",
language = "English",
volume = "63",
pages = "1236--1247",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity

AU - Jall, Sigrid

AU - De Angelis, Meri

AU - Lundsgaard, Annemarie

AU - Fritzen, Andreas Mæchel

AU - Nicolaisen, Trine Sand

AU - Klein, Anders Bue

AU - Novikoff, Aaron

AU - Sachs, Stephan

AU - Richter, Erik A.

AU - Kiens, Bente

AU - Schramm, Karl-Werner

AU - Tschöp, Matthias H

AU - Stemmer, Kerstin

AU - Clemmensen, Christoffer

AU - Müller, Timo D

AU - Kleinert, Maximilian

N1 - CURIS 2020 NEXS 040

PY - 2020

Y1 - 2020

N2 - Aims/Hypothesis: Treatment with the α3β4 nicotinic acetylcholine receptor (nAChR) agonist, 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), improves glucose tolerance in diet-induced obese (DIO) mice, but the physiological and molecular mechanisms are unknown.Methods: DMPP (10 mg/kg body weight, s.c.) was administered either in a single injection (acute) or daily for up to 14 days (chronic) in DIO wild-type (WT) and Chrnb4 knockout (KO) mice and glucose tolerance, tissue-specific tracer-based glucose metabolism, and insulin signalling were assessed.Results: In WT mice, but not in Chrnb4 KO mice, single acute treatment with DMPP induced transient hyperglycaemia, which was accompanied by high plasma adrenaline (epinephrine) levels, upregulated hepatic gluconeogenic genes, and decreased hepatic glycogen content. In contrast to these acute effects, chronic DMPP treatment in WT mice elicited improvements in glucose tolerance already evident after three consecutive days of DMPP treatment. After seven days of DMPP treatment, glucose tolerance was markedly improved, also in comparison with mice that were pair-fed to DMPP-treated mice. The glycaemic benefit of chronic DMPP was absent in Chrnb4 KO mice. Chronic DMPP increased insulin-stimulated glucose clearance into brown adipose tissue (+69%), heart (+93%), gastrocnemius muscle (+74%) and quadriceps muscle (+59%), with no effect in white adipose tissues. After chronic DMPP treatment, plasma adrenaline levels did not increase following an injection with DMPP. In glucose-stimulated skeletal muscle, we detected a decreased phosphorylation of the inhibitory Ser640 phosphorylation site on glycogen synthase and a congruent increase in glycogen accumulation following chronic DMPP treatment.Conclusions/Interpretation: Our data suggest that DMPP acutely induces adrenaline release and hepatic glycogenolysis, while chronic DMPP-mediated activation of β4-containing nAChRs improves peripheral insulin sensitivity independently of changes in body weight via mechanisms that could involve increased non-oxidative glucose disposal into skeletal muscle.

AB - Aims/Hypothesis: Treatment with the α3β4 nicotinic acetylcholine receptor (nAChR) agonist, 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), improves glucose tolerance in diet-induced obese (DIO) mice, but the physiological and molecular mechanisms are unknown.Methods: DMPP (10 mg/kg body weight, s.c.) was administered either in a single injection (acute) or daily for up to 14 days (chronic) in DIO wild-type (WT) and Chrnb4 knockout (KO) mice and glucose tolerance, tissue-specific tracer-based glucose metabolism, and insulin signalling were assessed.Results: In WT mice, but not in Chrnb4 KO mice, single acute treatment with DMPP induced transient hyperglycaemia, which was accompanied by high plasma adrenaline (epinephrine) levels, upregulated hepatic gluconeogenic genes, and decreased hepatic glycogen content. In contrast to these acute effects, chronic DMPP treatment in WT mice elicited improvements in glucose tolerance already evident after three consecutive days of DMPP treatment. After seven days of DMPP treatment, glucose tolerance was markedly improved, also in comparison with mice that were pair-fed to DMPP-treated mice. The glycaemic benefit of chronic DMPP was absent in Chrnb4 KO mice. Chronic DMPP increased insulin-stimulated glucose clearance into brown adipose tissue (+69%), heart (+93%), gastrocnemius muscle (+74%) and quadriceps muscle (+59%), with no effect in white adipose tissues. After chronic DMPP treatment, plasma adrenaline levels did not increase following an injection with DMPP. In glucose-stimulated skeletal muscle, we detected a decreased phosphorylation of the inhibitory Ser640 phosphorylation site on glycogen synthase and a congruent increase in glycogen accumulation following chronic DMPP treatment.Conclusions/Interpretation: Our data suggest that DMPP acutely induces adrenaline release and hepatic glycogenolysis, while chronic DMPP-mediated activation of β4-containing nAChRs improves peripheral insulin sensitivity independently of changes in body weight via mechanisms that could involve increased non-oxidative glucose disposal into skeletal muscle.

KW - Faculty of Science

KW - Catecholamine

KW - Glucose metabolism

KW - Glucose tolerance

KW - Hyperglycaemia

KW - Insulin sensitivity

KW - Nicotinic acetylcholine receptor

KW - Pharmacology

U2 - 10.1007/s00125-020-05117-4

DO - 10.1007/s00125-020-05117-4

M3 - Journal article

C2 - 32140744

VL - 63

SP - 1236

EP - 1247

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 6

ER -

ID: 237514470